TL;DR
The Supreme Court ruled that the Food and Drug Administration (FDA) violated due process when it re-certified and distributed contraceptive drugs without proper notice and hearing for opposing parties. The Court emphasized that even in administrative proceedings, fundamental fairness requires that individuals and groups be given a chance to present their side, especially when decisions impact constitutionally protected rights like the right to life of the unborn. The FDA is now mandated to create rules of procedure for drug certification that include notice, hearing, and consideration of opposition, ensuring a transparent and fair process.
Balancing Public Health and Due Process: A Case of Contraceptive Certification
This case revolves around the petitions filed by Alliance for the Family Foundation, Philippines, Inc. (ALFI) questioning the Food and Drug Administration’s (FDA) re-certification of several contraceptive drugs, including Implanon and Implanon NXT. ALFI argued that these contraceptives could be abortifacients and that the FDA failed to observe due process in their re-certification by not providing notice or holding public hearings, especially given ALFI’s formal opposition. The petitioners sought to nullify the certifications and enjoin the distribution of these drugs, asserting that the FDA’s actions violated their right to due process and the constitutional right to life of the unborn.
The Supreme Court addressed two key issues: whether the petitioners had legal standing and whether the FDA indeed violated due process. The Court affirmed ALFI’s standing, recognizing the transcendental importance of issues concerning reproductive health and the right to life, especially in light of the earlier Imbong v. Ochoa case which dealt with the constitutionality of the RH Law. Building on this principle, the Court then examined the FDA’s actions against the established tenets of procedural due process. It underscored that due process, a cornerstone of the Bill of Rights, mandates both substantive and procedural fairness. While administrative proceedings are generally more flexible, they are not exempt from the fundamental right to be heard.
The Court cited the landmark case of Ang Tibay v. CIR, reiterating the cardinal rights in administrative proceedings, including the right to a hearing, consideration of evidence, and decisions based on evidence presented. In this instance, the FDA issued certifications and proceeded with drug distribution without demonstrably addressing ALFI’s opposition or conducting hearings. The Supreme Court found this lack of procedural rigor to be a violation of due process, rendering the FDA’s certifications and subsequent actions invalid. The Court emphasized,
“Due to the failure of the respondents to observe and comply with the basic requirements of due process, the Court is of the view that the certifications/re-certifications and the distribution of the questioned contraceptive drugs by the respondents should be struck down as violative of the constitutional right to due process.”
Furthermore, the Court addressed the appeal process for FDA decisions. While existing regulations suggested appeals to the Secretary of Health and then to the Office of the President, the Supreme Court clarified that given the Secretary of Health was a respondent in this case, direct appeals from the FDA should be made to the Court of Appeals via a Petition for Review under Rule 43. This adjustment aimed to expedite the resolution of such critical controversies, especially those involving the right to life. The Court also denied the contempt petition against the respondents, finding insufficient evidence of deliberate disobedience of the Temporary Restraining Order (TRO). However, the Court maintained the TRO pending the FDA’s compliance with due process requirements.
In a significant directive, the Supreme Court mandated the FDA to formulate clear rules of procedure for the screening and approval of contraceptive drugs. These rules must incorporate minimum due process standards: publication, notice, hearing, intervention rights for interested parties, strict adherence to constitutional standards regarding contraceptives (non-abortifacient), resolution of doubts in favor of the unborn’s right to life, and compliance with Ang Tibay principles. The Department of Health was also directed to create guidelines for the purchase and distribution of contraceptives, ensuring they are not used as abortifacients and safeguarding the right to life. The Court’s decision underscores the principle that administrative efficiency cannot override fundamental rights, and that due process is essential even in technical regulatory processes.
FAQs
| What was the key issue in this case? | The central issue was whether the FDA violated the petitioners’ right to due process when it re-certified contraceptive drugs without notice and hearing, particularly concerning the drugs’ potential abortifacient nature. |
| What is the significance of ‘due process’ in this case? | Due process ensures fairness in legal and administrative proceedings. In this case, it meant the FDA should have provided notice and a hearing to parties opposing the drug certifications, allowing them to present their concerns. |
| What did the Supreme Court order the FDA to do? | The Court ordered the FDA to conduct hearings on the re-certified contraceptives, allowing petitioners to be heard, and to formulate rules of procedure for drug certification that include due process requirements like notice and hearing. |
| What are the ‘Ang Tibay’ principles mentioned in the decision? | The ‘Ang Tibay’ principles are cardinal rights in administrative proceedings, ensuring fair hearings, evidence consideration, substantial evidence for decisions, and reasoned decisions based on the record. |
| What is the practical effect of this ruling? | The ruling ensures greater transparency and fairness in the FDA’s drug certification process, particularly for contraceptives. It mandates that public concerns and oppositions must be heard and considered, especially regarding products with ethical and health implications. |
| Did the Supreme Court rule on whether the contraceptives are abortifacients? | No, the Supreme Court did not rule on whether the contraceptives are abortifacients. It focused on the procedural due process violation by the FDA and directed the FDA to conduct hearings to determine this, following due process. |
For inquiries regarding the application of this ruling to specific circumstances, please contact Atty. Gabriel Ablola through gaboogle.com or via email at connect@gaboogle.com.
Disclaimer: This analysis is provided for informational purposes only and does not constitute legal advice. For specific legal guidance tailored to your situation, please consult with a qualified attorney.
Source: Alliance for the Family Foundation, Philippines, Inc. (ALFI) v. Garin, G.R. No. 217872, August 24, 2016

Leave a Reply